deCODE biostructures Expands Collaboration with InterMune
News Jun 12, 2007
deCODE biostructures, Inc. announces the initiation of a third research project with InterMune, Inc. Under the research agreement, deCODE biostructures will conduct screening of its Fragments of Life™ library against an InterMune target.
The research fee and milestone-based research collaboration will utilize deCODE's proprietary Fragments of Life™ technology and crystallographic methods to enable identification of new chemical intellectual property for small molecule inhibitors of InterMune's drug target.
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE